National Institute of Allergy and Infectious Diseases (NIAID): Influenza in Birds trials

The registry lists 47 Influenza in Birds studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 30Phase 2 20No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 2017 A/H7N9 IIV RevaccinationCompletedNCT03738241Phase 2Results posted
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 2Results posted
• 2013/2017 H7N9 Prime-Boost IntervalCompletedNCT03589807Phase 2Results posted
• Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4CompletedNCT03318315Phase 2Results posted
• Sanofi 2017 H7N9 With/Without AS03 in Adults/ElderlyCompletedNCT03312231Phase 2Results posted
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 2Results posted
• Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2Results posted
• Immune Responses to H5N1 Vaccine With and Without AS03 AdjuvantCompletedNCT01578317Phase 1/2Results posted
• H5N1 Priming and Boosting StrategiesCompletedNCT00703053Phase 2Results posted
• Development of Immune Globulin Treatment for Avian FluTerminatedNCT00383071Phase 2Results posted
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian InfluenzaCompletedNCT00298233Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 1
• H5N1 With or Without Topical Aldara in Healthy AdultsCompletedNCT03472976Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedNCT03014310Phase 1
• Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 AdjuvantCompletedNCT02957656Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 1
• H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 2
• Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years OldCompletedNCT02274545Phase 1
• A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedNCT02251288Phase 1
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
• H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...CompletedNCT02206464Phase 1
• Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying IntervalsCompletedNCT02151344Phase 1
• Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy AdultsCompletedNCT01995695Phase 1
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
• H5N1 Vaccination With and Without AS03: Systems Biology AnalysisCompletedNCT01573312Phase 1
• Experimental AD4-H5-VTN Vaccine in Healthy VolunteersCompletedNCT01443936Phase 1
• Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza VaccineCompletedNCT01443663Phase 1
• H5N1 Mix and Match With AS03CompletedNCT01317758Phase 1
• H5N1 Mix and Match With MF59CompletedNCT01317745Phase 1
• An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...CompletedNCT01086657Phase 1
• Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 VaccinesCompletedNCT01086566Phase 1
• Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7CompletedNCT00922259Phase 1
• H5N1 (Clade 2) Vaccination of Adults and ElderlyCompletedNCT00680069Phase 1/2
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyCompletedNCT00489931Phase 1
• China Case Control Avian InfluenzaCompletedNCT00428753
• Prospective Study of AI H5N1 in ChinaCompletedNCT00428493
• Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 1
• Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in AdultsCompletedNCT00382980Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)CompletedNCT00380237Phase 1
• Cell-Mediated Immune Responses to Influenza A/H5N1 VaccineCompletedNCT00311727Not applicable
• Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing FacilitiesCompletedNCT00311649Phase 1/2
• H5N1 Vaccine Intramuscular Versus Intradermal in Healthy AdultsCompletedNCT00310206Phase 1
• Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) VaccineCompletedNCT00240903Phase 1
• Inactivated Influenza A/H5N1 Vaccine in the ElderlyCompletedNCT00230750Phase 1/2
• A/H5N1 Vaccine in Healthy Children Aged 2-9 YearsCompletedNCT00133536Phase 1/2
• A/H5N1in Adult - AventisCompletedNCT00115986Phase 1/2